Adocia SA (EPA: ADOC) is a French clinical-stage biotechnology company focused on innovative formulations for diabetes and metabolic diseases. Using its proprietary BioChaperone platform, Adocia aims to improve the performance of insulin and other injectable therapies. Its stock tends to move on clinical trial outcomes, partnership announcements, and progress in advancing its pipeline toward commercialization.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026


